Cambridge, Mass., USA - September 4, 2015, Cambridge, Mass., USA - Eleven Biotherapeutics, a clinical-stage biopharmaceutical company, announced the promotions of Gary Sternberg to chief business officer and John McCabe to SVP of finance.
Article continues below
Mr. Sternberg has served as Executive Vice President, Corporate and Business Development of Eleven since May 2014, and brings more than 20 years of ophthalmology expertise to the company, including pharmaceutical industry experience and medical practice.
Prior to joining Eleven, Mr. Sternberg served as Therapeutic Head of Ophthalmic Medical Affairs in the United States for Genentech, a division of the Roche Group. Previously, he served as Executive Director, Strategic Transactions Group for Bristol-Myers Squibb, with responsibility for licensing across multiple therapeutic areas.
Earlier in his career, Dr. Sternberg served as Chief Business Officer for Fovea Pharmaceuticals, an ophthalmic-focused biotechnology company, and as Vice President of Alliance Management and Business Development for Eyetech Pharmaceuticals and (OSI) Eyetech, OSI Pharmaceuticals’s eyecare subsidiary.
Dr. Sternberg was a practicing board-certified ophthalmologist prior to joining the pharmaceutical industry. He earned his MD from the State University of New York – Brooklyn and conducted his postgraduate residency training in Ophthalmology and fellowship training in Cornea, External Diseases and Refractive Surgery at Mount Sinai Medical Center. He obtained his MBA from theUniversity of Chicago.
Mr. McCabe is also Eleven’s Principal Financial and Accounting Officer. He has served as Vice President of Finance and Business Operations of Eleven since June 2013 and asTreasurer since September 2012.
Mr. McCabe served as Senior Director of Finance of Eleven from April 2012 to June 2013, bringing more than 20 years of finance and accounting experience to the company. Prior to joining Eleven, he was Vice President of Finance at Clinical Data, a drug development company that was acquired by Forest Laboratories.
Previously, Mr. McCabe served in several financial roles at Interleukin Genetics, Inc., a genetics-focused personalized health company, and SatCon Technology Corporation, a developer of innovative power conversion solutions. ■